Skip to main content

MediChem Awarded NIH Grant to Further Protein Crystallization Effort

NEW YORK, June 13 – Medichem Life Sciences’ Emerald BioStructures division was awarded a Phase II grant from the National Institutes of Health for development of protein crystallization tools, the company announced Wednesday.

The SBIR Phase II grant follows a Phase I grant that supported Emerald’s development of its EmeraldEngine protein crystallization technology platform, which includes robotic automation, software and databases, and expression and membrane crystallization technologies. The Phase II grant is titled “Crystallization Tools for Structural Genomics.”

“Protein crystallization is currently the rate-limiting step in structural proteomics,” MediChem CEO Michael Flavin said in a statement. “Our proprietary technologies enable us to crystallize proteins faster than ever before. This Phase II grant will fund the development of technologies that speed up the process even more.” 

After protein crystallization, Emerald, via a proprietary user agreement, uses Argonne National Laboratory’s Advanced Photon Source to collect X-ray diffraction data and obtain a high resolution rendering of the proteins’ three-dimensional structures.

Chicago-based MediChem acquired Emerald in June 2000. The size of the grant was not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.